CALLAGHAN MICHAEL J 4

4 · RENOVIS INC · Filed Feb 11, 2004

Form 4

Period: 2004-02-10

Director

Transactions

Conversion
Common Stock
2004-02-10+2,577,777→ 2,577,777 total(indirect: By Fund)
Conversion
Common Stock
2004-02-10+244,444→ 244,444 total(indirect: By Fund)
Conversion
Common Stock
2004-02-10+211,277→ 211,277 total(indirect: By Fund)
Conversion
Series D Preferred Stock
2004-02-10−1,100,000→ 0 total(indirect: By Fund)
→ Common Stock (244,444 underlying)
Conversion
Series D Preferred Stock
2004-02-10−11,600,000→ 0 total(indirect: By Fund)
→ Common Stock (2,577,777 underlying)
Conversion
Series E Preferred Stock
2004-02-10−334,967→ 0 total(indirect: By Fund)
→ Common Stock (74,437 underlying)
Conversion
Series E Preferred Stock
2004-02-10−642,857→ 0 total(indirect: By Fund)
→ Common Stock (285,714 underlying)
Conversion
Common Stock
2004-02-10+285,714→ 285,714 total(indirect: By Fund)
Conversion
Series E Preferred Stock
2004-02-10−950,747→ 0 total(indirect: By Fund)
→ Common Stock (211,277 underlying)
Conversion
Common Stock
2004-02-10+74,437→ 74,437 total(indirect: By Fund)
Conversion
Series E Preferred Stock
2004-02-10−1,285,714→ 0 total(indirect: By Fund)
→ Common Stock (142,857 underlying)
Conversion
Common Stock
2004-02-10+142,857→ 142,857 total(indirect: By Fund)

Footnotes (12)

[F1]Reflects the 1-for-4.5 reverse stock split effected prior to the effectiveness of the Issuer's initial public offering.
[F10]SC Biotechnology Development Fund LP.
[F11]Does not reflect the 1-for-4.5 reverse stock split effected prior to the effectiveness of the Issuer's initial public offering.
[F12]Expiration date is irrelevant.
[F2]The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in the named fund, if any, and the inclusion of these shares shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
[F3]Each one share of Series D Preferred Stock automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering.
[F4]CentPharm, LLC.
[F5]The shares are held by Embassy & Co. as escrow agent for CentPharm, LLC. CentPharm, LLC controls the voting of the shares held by Embassy & Co. as escrow agent.
[F6]Each one share of Series E Preferred Stock automatically converted at into one share of Common Stock upon the closing of the Issuer's initial public offering.
[F7]MDS Life Sciences Technology Fund II NC Limited Partnership.
[F8]MDS Life Sciences Technology Fund II Quebec Limited Partnership.
[F9]MLII Co-Investment Fund NC Limited Partnership.

Documents

1 file